Janssen-Cilag Ltd.

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.janssen.com

Clinical Trials

A Real-world Study in Participants With Smoldering Multiple Myeloma

Recruiting

Conditions: Smoldering Multiple Myeloma

First Posted Date: 2024-06-25

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen-Cilag Ltd.

Target Recruit Count: 450

Registration Number: NCT06472778

Locations: 🇫🇷
CHU Montpellier, Montpellier, France
🇫🇷
CH Rene Dubos, Pontoise cedex, France
🇮🇹
Azienda Ospedaliera Universitaria Careggi, Firenze, Italy

and more 15 locations

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

Phase 3

Recruiting

Conditions: Crohn's Disease

Interventions: Drug: Guselkumab

First Posted Date: 2024-05-10

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen-Cilag Ltd.

Target Recruit Count: 112

Registration Number: NCT06408935

Locations: 🇨🇦
Western University & London Health Sciences Centre, London, Ontario, Canada
🇩🇪
Charite Universitatsmedizin Berlin, Berlin, Germany
🇩🇪
Medizinisches Versorgungszentrum (MVZ) Dachau, Dachau, Germany

and more 15 locations

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Recruiting

Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)

Interventions: Other: Teclistamab
Other: Talquetamab

First Posted Date: 2024-02-29

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen-Cilag Ltd.

Target Recruit Count: 600

Registration Number: NCT06285318

Locations: 🇮🇹
Azienda Ospedaliera Universitaria Federico II, Napoli, Italy
🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇮🇹
AOU Careggi, Firenze, Italy

and more 33 locations

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

Recruiting

Conditions: Metastatic Hormone-sensitive Prostate Cancer

Interventions: Drug: Apalutamide
Drug: Enzalutamide

First Posted Date: 2023-06-13

Last Posted Date: 2024-12-05

Lead Sponsor: Janssen-Cilag Ltd.

Target Recruit Count: 450

Registration Number: NCT05901649

Locations: 🇩🇪
Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz, Germany
🇦🇹
Klinikum Wels Grieskirchen, Wels, Austria
🇦🇹
Akh Wien, Wien, Austria

and more 45 locations

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

Phase 3

Recruiting

Conditions: Fistulizing Crohns Disease
Perianal Crohns Disease

Interventions: Drug: Guselkumab
Drug: Placebo

First Posted Date: 2022-04-26

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen-Cilag Ltd.

Target Recruit Count: 280

Registration Number: NCT05347095

Locations: 🇯🇵
Osaka University Hospital, Suita, Japan
🇯🇵
Kyorin University Hospital, Tokyo, Japan
🇯🇵
Ieda Hospital, Toyota, Japan

and more 143 locations

Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis

Phase 4

Terminated

Conditions: Psoriasis

Interventions: Drug: Guselkumab

First Posted Date: 2021-11-18

Last Posted Date: 2023-08-24

Lead Sponsor: Janssen-Cilag Ltd.

Target Recruit Count: 15

Registration Number: NCT05125679

Locations: 🇬🇷
Attikon Hospital, Athens, Greece
🇮🇹
Ospedale San Giovanni di Dio, Cagliari, Italy
🇩🇪
Universitatsklinikum Frankfurt, Frankfurt, Germany

and more 2 locations

A Study of Participants With Moderate or Severe Major Depressive Disorder (MDD) Requiring Urgent Symptom Control in a Psychiatric Emergency

Not yet recruiting

Conditions: Depressive Disorder, Major

First Posted Date: 2021-04-02

Last Posted Date: 2024-04-24

Lead Sponsor: Janssen-Cilag Ltd.

Target Recruit Count: 220

Registration Number: NCT04829669

Locations: 🇬🇧
Greater Manchester Mental Health NHSFT, Manchester, United Kingdom

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

Phase 4

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Esketamine
Drug: SSRI/SNRI

First Posted Date: 2021-04-02

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen-Cilag Ltd.

Target Recruit Count: 183

Registration Number: NCT04829318

Locations: 🇦🇷
Sanatorio Prof Leon S Morra S A, Cordoba, Argentina
🇦🇷
Instituto de Neurociencias San Agustin, La Plata, Argentina
🇨🇿
A Shine S R O, Plzen, Czechia

and more 55 locations

A Study to Evaluate the Impact of Care4Today® IBD, a Smart System to Facilitate the Management of Crohn's Disease by Patients and Health Care Providers

Terminated

Conditions: Crohn Disease

Interventions: Other: No intervention

First Posted Date: 2020-01-18

Last Posted Date: 2023-07-03

Lead Sponsor: Janssen-Cilag Ltd.

Target Recruit Count: 32

Registration Number: NCT04232228

Locations: 🇬🇧
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

Completed

Conditions: Multiple Myeloma

Interventions: Other: No intervention

First Posted Date: 2019-07-29

Last Posted Date: 2023-12-08

Lead Sponsor: Janssen-Cilag Ltd.

Target Recruit Count: 254

Registration Number: NCT04035226

Locations: 🇪🇸
Hosp. Puerta Del Mar, Cadiz, Spain
🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇮🇹
Universita degli Studi di Padova - Azienda Ospedaliera di Pa, Padova, Italy

and more 72 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy